The Ghost Research Haunting Nordic Medical Trials

Please enable cookies.

Error
1005

Ray ID: 87aca4c0bc60849e •
2024-04-27 06:09:24 UTC

What happened?

The owner of this website (www.medscape.com) has banned the autonomous system number (ASN) your IP address is in (47583) from accessing this website.

Was this page helpful?

Thank you for your feedback!

Cloudflare Ray ID: 87aca4c0bc60849e

Your IP:

185.124.111.116


Performance & security by Cloudflare

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Weight-loss surgery: Is it an option for you? thumbnail

Weight-loss surgery: Is it an option for you?

Weight-loss surgery: Is it an option for you?Learn about the criteria you must meet to have weight-loss surgery.By Mayo Clinic Staff Weight-loss surgery changes the shape and function of your digestive system. This surgery may help you lose weight and manage medical conditions related to obesity. These conditions include diabetes, obstructive sleep apnea, and risk
Read More
NYU Langone brings goals of care data into EHR workflow thumbnail

NYU Langone brings goals of care data into EHR workflow

The Medical Orders for Life-Sustaining Treatment, or MOLST, program aims to improve care for seriously ill patients and tailor treatment to their end-of-life preferences. Based on communication between the patient and their physician or NP, the eight-step protocol guides treatment for palliative care and during advanced illness and in emergencies. In New York, a statewide…
Read More
Radioligand Therapy Continues to Show Promise for Metastatic CRPC thumbnail

Radioligand Therapy Continues to Show Promise for Metastatic CRPC

Oncology/Hematology > Prostate Cancer — Median OS of 15.5 months, PFS of 7.9 months with Ac-225-PSMA in heavily treated patients by Charles Bankhead, Senior Editor, MedPage Today February 16, 2024 Radioligand therapy (RLT) with actinium-225 targeting prostate-specific membrane antigen (225Ac-PSMA) had a "substantial antitumor effect" in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC), a large
Read More
Index Of News
Total
0
Share